Cencora/$COR

13:30
15:10
16:45
18:25
20:00
1D1W1MYTD1Y5YMAX

About Cencora

Cencora is one of three leading domestic pharmaceutical wholesalers. It sources and distributes branded, generic, and specialty pharmaceutical products to pharmacies (retail chains, independent, and mail order), hospital networks, and healthcare providers. It and McKesson and Cardinal Health constitute over 90% of the US pharmaceutical wholesale industry. Cencora also provides commercialization services for manufacturers of pharmaceuticals and medical devices, global specialty drug logistics (World Courier), and animal health product distribution (MWI Animal Health). Cencora expanded its international presence in 2021 by purchasing Alliance Healthcare, one of the leading drug wholesalers in Europe.

Ticker

$COR
Sector

Primary listing

NYSE

Employees

44,000

Cencora Metrics

BasicAdvanced
$59B
31.26
$9.68
0.58
$2.20
0.73%

What the Analysts think about Cencora

Analyst ratings (Buy, Hold, Sell) for Cencora stock.

Bulls say / Bears say

Cencora’s $4.4 billion acquisition of Retina Consultants of America adds nearly 300 retina specialists to its portfolio, diversifying its service offerings into higher-margin physician services and strengthening its specialty care presence. (Reuters)
The company raised its fiscal 2025 profit forecast to $15.85–$16.00 per share, up from $15.70–$15.95, driven by strong demand for high-margin specialty therapies and GLP-1 weight-loss medications, suggesting strong earnings momentum in its core U.S. Healthcare Solutions segment. (Barron’s)
Cencora is among the potential bidders for Europe’s Walden Group, a €1 billion pharmaceutical logistics company, signaling its strategy to deepen global specialty drug logistics capabilities and speed up international growth. (Bloomberg)
Data summarised monthly by Lightyear AI. Last updated on 7 Sept 2025.

Cencora Financial Performance

Revenues and expenses
QuarterlyAnnual
Q3 24
QoQ growth
Revenue
$37B
-39.75%
Net income
$45B
107.52%
Profit margin
37.65%
6.78%

Cencora Earnings Performance

Company profitability
QuarterlyAnnual
Q4 23
Q1 24
Q2 24
Q3 24
Q4 24
Actual
$3.69
$2.85
$2.45
$2.42
-
Expected
$3.55
$2.61
$2.05
$2.31
$3.94
Surprise
3.94%
9.20%
19.51%
4.63%
-
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.

Buy $COR

Sign up or log in to buy
Capital at risk
Market closed

Upcoming events

No upcoming events
FAQs